ストックスクリーナーアプリを入手
62.67
0.63%
0.39
アフターアワーズ：
62.87
0.20
+0.32%
前日終値:
$62.28
開ける：
$62.65
24時間の取引高:
1.19M
Relative Volume:
0.84
時価総額：
$5.23B
収益：
$1.73B
当期純損益:
$682.64M
株価収益率:
8.1007
EPS:
7.7364
ネットキャッシュフロー:
$411.18M
1週間 パフォーマンス:
-4.13%
1か月 パフォーマンス:
-14.70%
6か月 パフォーマンス:
-6.11%
1年 パフォーマンス:
+8.35%
1日の値動き範囲:
$61.66
$63.44
1週間の範囲:
$61.23
$66.58
52週間の値動き範囲:
$57.78
$90.87
Ptc Therapeutics Inc Stock (PTCT) Company Profile
名前
Ptc Therapeutics Inc
セクター
電話
(908) 222-7000
住所
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
62.67 | 5.23B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Raymond James | Outperform |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-12-01 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-17 | 開始されました | Truist | Buy |
| 2025-05-09 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-05-07 | アップグレード | Citigroup | Sell → Neutral |
| 2025-03-11 | アップグレード | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 開始されました | Scotiabank | Sector Perform |
| 2024-12-13 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-09-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-08-26 | 再開されました | UBS | Buy |
| 2024-05-20 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-10-30 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-10-27 | ダウングレード | Citigroup | Neutral → Sell |
| 2023-10-06 | ダウングレード | Truist | Buy → Hold |
| 2023-09-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-09-15 | ダウングレード | Raymond James | Outperform → Underperform |
| 2023-03-17 | 開始されました | SVB Securities | Market Perform |
| 2022-12-14 | 開始されました | Goldman | Sell |
| 2022-09-12 | 開始されました | Jefferies | Buy |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-10-18 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-29 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-01-05 | アップグレード | Citigroup | Neutral → Buy |
| 2020-11-30 | ダウングレード | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-10-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-04-09 | アップグレード | Citigroup | Neutral → Buy |
| 2020-02-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-02-20 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-05-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 開始されました | Bernstein | Outperform |
| 2018-10-03 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 開始されました | Credit Suisse | Outperform |
| 2018-06-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2017-10-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | ダウングレード | JP Morgan | Neutral → Underweight |
すべてを表示
Ptc Therapeutics Inc (PTCT) 最新ニュース
37 new hires get options to buy PTC shares at $65.96 - Stock Titan
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo! Finance Canada
PTC Therapeutics stock gets a Fabry therapy catalyst - AD HOC NEWS
PTC Therapeutics stock rises as third quarter data strengthen outlook - AD HOC NEWS
(PTCT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
PTC Therapeutics, Inc. (PTCT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cantor raises PTC Therapeutics stock price target on Fabry deal By Investing.com - Investing.com Canada
Cantor Fitzgerald Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $137.00 - MarketBeat
Cantor Fitzgerald maintains Overweight rating on PTC Therapeutics, $137 price target - TradingView
PTC Therapeutics completes ST-920 gene therapy acquisition By Investing.com - Investing.com Nigeria
PTC Therapeutics completes ST-920 gene therapy acquisition - Investing.com
PTC Therapeutics Closes Acquisition of the ST-920 Gene Therapy for Fabry Disease - finance.yahoo.com
PTC Completes Acquisition of ST-920, BLA Submission Expected in Q4 2026 - TradingView
A one-time gene therapy for Fabry disease is now PTC’s. FDA filing expected later in 2026. - Stock Titan
PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress - finance.yahoo.com
Bank of America Corp DE Takes $118.46 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics director Schmertzler sells $1.35m shares - Investing.com
Wall Street Zen Upgrades PTC Therapeutics (NASDAQ:PTCT) to "Strong-Buy" - MarketBeat
PTC Therapeutics director Schmertzler sells $1.35m shares By Investing.com - Investing.com Nigeria
PTC Therapeutics (NASDAQ:PTCT) Director Sells 10,000 Shares - MarketBeat
PTC Therapeutics Director Michael Schmertzler Executes 20,000 Share Sale Under 10b5-1 Trading Plan - Kalkine Media
PTC Therapeutics (NASDAQ: PTCT) director offloads 20,000 shares under trading plan - Stock Titan
Is PTC Therapeutics (PTCT) Undervalued After Its Recent Pullback? - simplywall.st
ETFs Investing in PTC Therapeutics, Inc. Stocks - TradingView
PTC Therapeutics at Morgan Stanley conference: sephience drives outlook By Investing.com - Investing.com Nigeria
PTC Therapeutics, Inc. $PTCT Shares Sold by Engineers Gate Manager LP - MarketBeat
California State Teachers Retirement System Lowers Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Leerink Partners Begins Coverage on PTC Therapeutics (NASDAQ:PTCT) - MarketBeat
(PTCT) Volatility Zones as Tactical Triggers - Stock Traders Daily
PTC Therapeutics director Schmertzler sells $1.35m in stock - investing.com
PTC Therapeutics director Schmertzler sells $1.35m in stock By Investing.com - Investing.com India
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Director Sells 10,000 Shares of Stock - MarketBeat
Director stock sale at PTC Therapeutics (PTCT) ran on a preset 10b5-1 plan - Stock Titan
PTC Therapeutics at cantor healthcare conference: sephience drives growth By Investing.com - Investing.com Canada
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $2.32 Million in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics at Wells Fargo conference: sufiance drives growth plan By Investing.com - Investing.com Canada
Hsbc Holdings PLC Reduces Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
Corient Private Wealth LP Makes New Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - Eastern Progress
Wells Fargo Sticks to Its Buy Rating for PTC Therapeutics (PTCT) - theglobeandmail.com
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $109 - Moomoo
Moore Capital Management LP Acquires 30,894 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
Wellington Management Group LLP Raises Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
Empowered Funds LLC Acquires Shares of 81,271 PTC Therapeutics, Inc. $PTCT - MarketBeat
Legal & General Group Plc Makes New Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
Palo Alto Investors LP Invests $74.95 Million in PTC Therapeutics, Inc. $PTCT - MarketBeat
Hsbc Holdings PLC Takes $10.76 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc.: Upfront Payment of $111 Million, Plus Up to an Additional $100 Million in Contingent Milestone Payments >PTCT - Moomoo
PTC Therapeutics director Michael Schmertzler sells $1.8m in shares - Investing.com
Michael Schmertzler Sells 12,500 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Ptc Therapeutics Inc (PTCT) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):